|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||4.03 / 8.38|
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
In recent trading, shares of Keryx Biopharmaceuticals Inc. have crossed above the average analyst 12-month target price of $6.83, changing hands for $6.84/share.
Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading this week, for the December 15th expiration.
Investors eyeing a purchase of Keryx Biopharmaceuticals Inc. stock, but cautious about paying the going market price of $5.82/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Additional formularies expand unrestricted access to Auryxia to approximately 85 percent of phosphate binder patients across Medicare Part D and commercial insurance providers
Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in Keryx Biopharmaceuticals Inc. saw new options become available this week, for the February 2017 expiration.
Majority of patients when started on Auryxia achieved target serum phosphorus levels within six months of treatment
Investors in Keryx Biopharmaceuticals Inc. saw new options begin trading today, for the January 2019 expiration.
Auryxia is now available for prescription in the U.S.